Surgical therapy of end-stage heart failure: Understanding cell-mediated mechanisms interacting with myocardial damage

Ali Ghodsizad, Matthias Loebe, Christoph Piechaczek, Viktor Bordel, Matthias N. Ungerer, Igor Gregoric, Brian Bruckner, George P. Noon, Matthias Karck, Arjang Ruhparwar

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Worldwide, cardiovascular disease results in an estimated 14.3 million deaths per year, giving rise to an increased demand for alternative and advanced treatment. Current approaches include medical management, cardiac transplantation, device therapy, and, most recently, stem cell therapy. Research into cell-based therapies has shown this option to be a promising alternative to the conventional methods. In contrast to early trials, modern approaches now attempt to isolate specifc stem cells, as well as increase their numbers by means of amplifying in a culture environment. The method of delivery has also been improved to minimize the risk of micro-infarcts and embolization, which were often observed after the use of coronary catheterization. The latest approach entails direct, surgical, trans-epicardial injection of the stem cell mixture, as well as the use of tissue-engineered meshes consisting of embedded progenitor cells.

Original languageEnglish (US)
Pages (from-to)529-545
Number of pages17
JournalInternational Journal of Artificial Organs
Volume34
Issue number7
DOIs
StatePublished - Jul 2011
Externally publishedYes

Fingerprint

Stem cells
Stem Cells
Heart Failure
Cell- and Tissue-Based Therapy
Heart Transplantation
Therapeutics
Catheterization
Tissue
Cardiovascular Diseases
Equipment and Supplies
Injections
Research

Keywords

  • Heart failure
  • Left ventricular assist device (LVAD) implantation
  • Myocardial recovery
  • Regenerative therapy
  • Stem cell therapy

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Bioengineering
  • Medicine (miscellaneous)

Cite this

Surgical therapy of end-stage heart failure : Understanding cell-mediated mechanisms interacting with myocardial damage. / Ghodsizad, Ali; Loebe, Matthias; Piechaczek, Christoph; Bordel, Viktor; Ungerer, Matthias N.; Gregoric, Igor; Bruckner, Brian; Noon, George P.; Karck, Matthias; Ruhparwar, Arjang.

In: International Journal of Artificial Organs, Vol. 34, No. 7, 07.2011, p. 529-545.

Research output: Contribution to journalArticle

Ghodsizad, A, Loebe, M, Piechaczek, C, Bordel, V, Ungerer, MN, Gregoric, I, Bruckner, B, Noon, GP, Karck, M & Ruhparwar, A 2011, 'Surgical therapy of end-stage heart failure: Understanding cell-mediated mechanisms interacting with myocardial damage', International Journal of Artificial Organs, vol. 34, no. 7, pp. 529-545. https://doi.org/10.5301/ijao.5000004
Ghodsizad, Ali ; Loebe, Matthias ; Piechaczek, Christoph ; Bordel, Viktor ; Ungerer, Matthias N. ; Gregoric, Igor ; Bruckner, Brian ; Noon, George P. ; Karck, Matthias ; Ruhparwar, Arjang. / Surgical therapy of end-stage heart failure : Understanding cell-mediated mechanisms interacting with myocardial damage. In: International Journal of Artificial Organs. 2011 ; Vol. 34, No. 7. pp. 529-545.
@article{0b907b7a1d684d788809f36339d2a389,
title = "Surgical therapy of end-stage heart failure: Understanding cell-mediated mechanisms interacting with myocardial damage",
abstract = "Worldwide, cardiovascular disease results in an estimated 14.3 million deaths per year, giving rise to an increased demand for alternative and advanced treatment. Current approaches include medical management, cardiac transplantation, device therapy, and, most recently, stem cell therapy. Research into cell-based therapies has shown this option to be a promising alternative to the conventional methods. In contrast to early trials, modern approaches now attempt to isolate specifc stem cells, as well as increase their numbers by means of amplifying in a culture environment. The method of delivery has also been improved to minimize the risk of micro-infarcts and embolization, which were often observed after the use of coronary catheterization. The latest approach entails direct, surgical, trans-epicardial injection of the stem cell mixture, as well as the use of tissue-engineered meshes consisting of embedded progenitor cells.",
keywords = "Heart failure, Left ventricular assist device (LVAD) implantation, Myocardial recovery, Regenerative therapy, Stem cell therapy",
author = "Ali Ghodsizad and Matthias Loebe and Christoph Piechaczek and Viktor Bordel and Ungerer, {Matthias N.} and Igor Gregoric and Brian Bruckner and Noon, {George P.} and Matthias Karck and Arjang Ruhparwar",
year = "2011",
month = "7",
doi = "10.5301/ijao.5000004",
language = "English (US)",
volume = "34",
pages = "529--545",
journal = "International Journal of Artificial Organs",
issn = "0391-3988",
publisher = "Wichtig Publishing",
number = "7",

}

TY - JOUR

T1 - Surgical therapy of end-stage heart failure

T2 - Understanding cell-mediated mechanisms interacting with myocardial damage

AU - Ghodsizad, Ali

AU - Loebe, Matthias

AU - Piechaczek, Christoph

AU - Bordel, Viktor

AU - Ungerer, Matthias N.

AU - Gregoric, Igor

AU - Bruckner, Brian

AU - Noon, George P.

AU - Karck, Matthias

AU - Ruhparwar, Arjang

PY - 2011/7

Y1 - 2011/7

N2 - Worldwide, cardiovascular disease results in an estimated 14.3 million deaths per year, giving rise to an increased demand for alternative and advanced treatment. Current approaches include medical management, cardiac transplantation, device therapy, and, most recently, stem cell therapy. Research into cell-based therapies has shown this option to be a promising alternative to the conventional methods. In contrast to early trials, modern approaches now attempt to isolate specifc stem cells, as well as increase their numbers by means of amplifying in a culture environment. The method of delivery has also been improved to minimize the risk of micro-infarcts and embolization, which were often observed after the use of coronary catheterization. The latest approach entails direct, surgical, trans-epicardial injection of the stem cell mixture, as well as the use of tissue-engineered meshes consisting of embedded progenitor cells.

AB - Worldwide, cardiovascular disease results in an estimated 14.3 million deaths per year, giving rise to an increased demand for alternative and advanced treatment. Current approaches include medical management, cardiac transplantation, device therapy, and, most recently, stem cell therapy. Research into cell-based therapies has shown this option to be a promising alternative to the conventional methods. In contrast to early trials, modern approaches now attempt to isolate specifc stem cells, as well as increase their numbers by means of amplifying in a culture environment. The method of delivery has also been improved to minimize the risk of micro-infarcts and embolization, which were often observed after the use of coronary catheterization. The latest approach entails direct, surgical, trans-epicardial injection of the stem cell mixture, as well as the use of tissue-engineered meshes consisting of embedded progenitor cells.

KW - Heart failure

KW - Left ventricular assist device (LVAD) implantation

KW - Myocardial recovery

KW - Regenerative therapy

KW - Stem cell therapy

UR - http://www.scopus.com/inward/record.url?scp=79961070831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961070831&partnerID=8YFLogxK

U2 - 10.5301/ijao.5000004

DO - 10.5301/ijao.5000004

M3 - Article

C2 - 21786252

AN - SCOPUS:79961070831

VL - 34

SP - 529

EP - 545

JO - International Journal of Artificial Organs

JF - International Journal of Artificial Organs

SN - 0391-3988

IS - 7

ER -